|
1
|
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
|
PLoS One
|
2008
|
2.70
|
|
2
|
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.
|
Vaccine
|
2005
|
2.21
|
|
3
|
A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.
|
Vaccine
|
2009
|
2.12
|
|
4
|
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.
|
Nat Commun
|
2011
|
2.11
|
|
5
|
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections.
|
PLoS Pathog
|
2010
|
2.03
|
|
6
|
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
|
Infect Immun
|
2006
|
2.02
|
|
7
|
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
|
Mol Ther
|
2011
|
1.92
|
|
8
|
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
|
PLoS One
|
2008
|
1.81
|
|
9
|
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
|
Mol Ther
|
2012
|
1.76
|
|
10
|
Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design.
|
Proc Natl Acad Sci U S A
|
2008
|
1.69
|
|
11
|
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.
|
PLoS One
|
2007
|
1.60
|
|
12
|
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
|
PLoS One
|
2012
|
1.58
|
|
13
|
Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.
|
PLoS One
|
2008
|
1.54
|
|
14
|
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.
|
J Immunol
|
2009
|
1.50
|
|
15
|
Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.
|
PLoS Pathog
|
2012
|
1.43
|
|
16
|
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali.
|
Infect Immun
|
2009
|
1.39
|
|
17
|
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
|
Vaccine
|
2009
|
1.33
|
|
18
|
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.
|
J Infect Dis
|
2013
|
1.30
|
|
19
|
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
|
PLoS One
|
2011
|
1.27
|
|
20
|
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
|
PLoS One
|
2010
|
1.25
|
|
21
|
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
|
Vaccine
|
2009
|
1.19
|
|
22
|
The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.
|
Vaccine
|
2010
|
1.17
|
|
23
|
The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.
|
Vaccine
|
2009
|
1.13
|
|
24
|
Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen.
|
Infect Immun
|
2011
|
1.11
|
|
25
|
posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.
|
Infect Immun
|
2005
|
1.06
|
|
26
|
Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
|
Vaccine
|
2010
|
1.02
|
|
27
|
Subdomain 3 of Plasmodium falciparum VAR2CSA DBL3x is identified as a minimal chondroitin sulfate A-binding region.
|
J Biol Chem
|
2010
|
1.01
|
|
28
|
Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
|
PLoS One
|
2012
|
1.01
|
|
29
|
Analysis of the conformation and function of the Plasmodium falciparum merozoite proteins MTRAP and PTRAMP.
|
Eukaryot Cell
|
2012
|
0.99
|
|
30
|
A class of tricyclic compounds blocking malaria parasite oocyst development and transmission.
|
Antimicrob Agents Chemother
|
2012
|
0.98
|
|
31
|
Improving malaria control in West Africa: interruption of transmission as a paradigm shift.
|
Acta Trop
|
2011
|
0.96
|
|
32
|
Multiple pathways for Plasmodium ookinete invasion of the mosquito midgut.
|
Proc Natl Acad Sci U S A
|
2014
|
0.96
|
|
33
|
Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum.
|
PLoS One
|
2013
|
0.95
|
|
34
|
Excretory/secretory products from plerocercoids of Spirometra erinaceieuropaei suppress the TNF-alpha gene expression by reducing phosphorylation of ERK1/2 and p38 MAPK in macrophages.
|
Int J Parasitol
|
2002
|
0.86
|
|
35
|
Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine.
|
Malar J
|
2011
|
0.85
|
|
36
|
Plasmodium falciparum merozoite surface protein 1 blocks the proinflammatory protein S100P.
|
Proc Natl Acad Sci U S A
|
2012
|
0.84
|
|
37
|
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.
|
Infect Immun
|
2013
|
0.82
|
|
38
|
Effects of age, hemoglobin type and parasite strain on IgG recognition of Plasmodium falciparum-infected erythrocytes in Malian children.
|
PLoS One
|
2013
|
0.82
|
|
39
|
A glycoprotein from Spirometra erinaceieuropaei plerocercoids suppresses osteoclastogenesis and proinflammatory cytokine gene expression.
|
Int J Parasitol
|
2005
|
0.81
|
|
40
|
RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen.
|
Infect Immun
|
2013
|
0.80
|
|
41
|
Macrophage migration inhibitory factor homolog from Plasmodium yoelii modulates monocyte recruitment and activation in spleen during infection.
|
Parasitol Res
|
2011
|
0.79
|
|
42
|
Suppression of IP-10/CXCL10 gene expression in LPS- and/or IFN-γ-stimulated macrophages by parasite-secreted products.
|
Cell Immunol
|
2012
|
0.76
|
|
43
|
Immunisation against a serine protease inhibitor reduces intensity of Plasmodium berghei infection in mosquitoes.
|
Int J Parasitol
|
2013
|
0.76
|
|
44
|
Vaccine design via nonnegative lasso-based variable selection.
|
Stat Med
|
2015
|
0.75
|